Bevacizumab for the Treatment of Glioblastoma

por Gil-Gil, Miguel J., Mesia, Carlos, Rey, Montserrat, Bruna, Jordi
Publicado 2013

Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational “LORENA” study

por Redondo, Andrés, Ramos Vázquez, Manuel, Manso, Luis, Gil Gil, Miguel J, Garau Llinas, Isabel, García-Garre, Elisa, Rodríguez, César A, Chacón, José Ignacio, López-Vivanco, Guillermo
Publicado 2018

Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients

por Molina, David, Pérez-Beteta, Julián, Martínez-González, Alicia, Sepúlveda, Juan M., Peralta, Sergi, Gil-Gil, Miguel J., Reynes, Gaspar, Herrero, Ana, De Las Peñas, Ramón, Luque, Raquel, Capellades, Jaume, Balaña, Carmen, Pérez-García, Víctor M.
Publicado 2016

Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study

por Rosenthal, Mark, Clement, Paul M, Campone, Mario, Gil-Gil, Miguel J, DeGroot, John, Chinot, Olivier, Idbaih, Ahmed, Gan, Hui, Raizer, Jeffrey, Wen, Patrick Yung, Pineda, Estela, Donnet, Valerie, Mills, David, El-Hashimy, Mona, Mason, Warren
Publicado 2020

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Fina...

por Gil-Gil, Miguel J., Bellet, Meritxell, Bergamino, Milana, Morales, Serafín, Barnadas, Agustí, Manso, Luís, Saura, Cristina, Fernández-Ortega, Adela, Garcia-Martinez, Elena, Martinez-Jañez, Noelia, Melé, Mireia, Villagrasa, Patricia, Celiz, Pamela, Perez Martin, X., Ciruelos, Eva, Pernas, Sonia
Publicado 2021

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer

por Shi, Zhen, Wulfkuhle, Julia, Nowicka, Malgorzata, Gallagher, Rosa I., Saura, Cristina, Nuciforo, Paolo G., Calvo, Isabel, Andersen, Jay, Passos-Coelho, José Luis, Gil-Gil, Miguel J., Bermejo, Begoña, Pratt, Debra A., Ciruelos, Eva M., Villagrasa, Patricia, Wongchenko, Matthew J., Petricoin, Emanuel F., Oliveira, Mafalda, Isakoff, Steven J.
Publicado 2022

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study

por Lassman, Andrew B., Sepúlveda-Sánchez, Juan Manuel, Cloughesy, Timothy F., Gil-Gil, Miguel J., Puduvalli, Vinay K., Raizer, Jeffrey J., De Vos, Filip Y.F., Wen, Patrick Y., Butowski, Nicholas A., Clement, Paul M.J., Groves, Morris D., Belda-Iniesta, Cristóbal, Giglio, Pierre, Soifer, Harris S., Rowsey, Steven, Xu, Cindy, Avogadri, Francesca, Wei, Ge, Moran, Susan, Roth, Patrick
Publicado 2022

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIF...

por Di Cosimo, Serena, Pérez-García, José Manuel, Bellet, Meritxell, Dalenc, Florence, Gil Gil, Miguel J, Ruiz Borrego, Manuel, Gavilá, Joaquín, Sampayo-Cordero, Miguel, Aguirre, Elena, Schmid, Peter, Marmé, Frederik, Gligorov, Joseph, Schneeweiss, Andreas, Albanell, Joan, Zamora, Pilar, Wheatley, Duncan, Martínez-De Dueñas, Eduardo, Carañana, Vicente, Amillano, Kepa, Mina, Leonardo, Malfettone, Andrea, Cortés, Javier, Llombart-Cussac, Antonio
Publicado 2022